NCT01955200 - OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial | Biotech Hunter

Enrollment

1,724

Participants

Timeline

Start Date

October 5, 2013

Primary Completion Date

December 26, 2016

Study Completion Date

November 28, 2017

Conditions

Coronary Artery Disease

Interventions

DRUG

Clopidogrel

(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

DRUG

Cilostazol

(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

DRUG

Ticagrelor

(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.

DRUG

Clopidogrel

(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.

DRUG

Clopidogrel

(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.

Trial Locations (1)

First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors

collaborator

National Natural Science Foundation of China

OTHER_GOV

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER